Healthcare

Northzone (Web3)

Check: No current personal check range or active fund mandate is public. Historical Northzone investments include seed and Series A through later follow-ons, but third-party Northzone range estimates are stale and do not establish present authority. Confirm current capacity directly.

At Northzone, Markus invested across enterprise applications, infrastructure, developer products and healthcare, with a strong DACH footprint. His operating experience at digital-health company Kry shaped an appetite for founders modernizing regulated markets despite entrenched incentives. Later deals show a widening lens: Reonic digitizes renewable-energy installers; Duvo automates exception-heavy retail operations; CuspAI applies generative models and physics to materials discovery; Black Forest Labs builds frontier visual intelligence. Across them, the common pattern is deep domain experience, a clear operational bottleneck and software or AI that changes an established value chain.

General Catalyst

Check: No personal check-size range is published. His record includes seed investments and large later financings, but disclosed round totals belong to company financings and are not a personal range.

Neeraj backs ambitious founders building category-defining businesses in India, MENA, and the corridors linking those regions with global markets. His approach combines Venture Highway's earliest-stage founder access with General Catalyst's resilience themes: financial inclusion, health assurance, domestic defense and industrial capability, energy infrastructure, locally relevant consumer products, and regulated platforms that modernize large GDP-driving sectors.

First Round Capital

Check: First Round's published firm-wide initial checks are typically $1M–$7M, averaging about $3.5M; it has participated in rounds from $100K to $20M. No personal range is published for Bill.

Bill looks for pre-product-market-fit founders who reason from first principles: they decompose a complicated system to its atomic unit, find hidden leverage in overlooked mechanics, and build an unconventional solution from the inside out. His documented portfolio spans data and enterprise software, physical security, logistics, AI infrastructure, insurance claims, accounting automation, IT automation, healthcare access, robotics, and legal services.

Khosla Ventures

Check: In a 2020 first-person interview, Samir described a typical Khosla Seed Fund investment as roughly $1M–$2M, used as option-value capital to remove key risks before a larger Series A/B decision. Khosla's current Main Fund covers early through later stages, including total financings above $10M. These are historical/firm-level guideposts, not a guaranteed current personal range.

Samir prefers large, known markets where a radical technical risk can produce a 10x-better product. He treats small seed checks as option-value experiments: identify a potential billion-dollar outcome, use capital to remove a binary technical, team, or market-development risk, then redo the diligence and concentrate capital if the evidence improves. He rejects mechanical pro-rata, values non-consensus decisions, and believes uncapped upside justifies bold technical bets rather than conservative hit-rate optimization.

Khosla Ventures

Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.

Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.

Blockchain Capital

Check: No Melissa-specific Blockchain Capital check size or allocation authority is public. Her documented work is executive talent, leadership and board development for NEA portfolio companies. Crypto founders should use Blockchain Capital's investors; NEA portfolio leaders can engage her on talent and leadership.

Melissa's operating thesis is that exceptional companies require leaders who can scale themselves along with the organization. She works with founders and CEOs to build, develop, compensate and retain executive teams and boards. Her coaching framework distinguishes mentors, consultants and coaches, treats self-awareness and feedback as business inputs and recommends structured coach selection with a written spec, trial sessions and references. Blockchain Capital lists her only as an advisor; no personal crypto deal thesis should be inferred.

BoxGroup

Check: BoxGroup currently publishes a firm-wide maximum investment of $1M. Historical sources reported smaller firm checks and third-party profiles estimate $250K–$750K for Nimi, but no primary source confirms a current personal range.

Nimi is a generalist early-stage Partner with a long-running, publicly documented focus on healthcare and life sciences, fintech, marketplaces, and software. Her current activity extends that lens into AI-native healthcare, scientific agents, enterprise AI, and the financial infrastructure surrounding AI use. She applies BoxGroup's founder-first philosophy while testing whether the operating model, retention, sequencing, and economics can support the founder's category-scale ambition.

BoxGroup

Check: No reliable Arielle-specific check size is public. BoxGroup describes itself as an earliest-stage investor, but founders should confirm current round fit and allocation directly rather than relying on third-party range estimates.

Arielle invests within BoxGroup's broad earliest-stage mandate. Her differentiated documented context is technical and translational: Harvard bioengineering research, founding a postpartum medical-device project, product work in fertility AI and neuromodulation, mechanical engineering at a bioelectronic-medicine startup, and consulting at BCG. This supports a credible ability to evaluate user need, clinical workflow, product design, manufacturing, regulatory planning and commercialization in technical health businesses. It does not establish an exclusive healthcare mandate or a personally published investment thesis.

General Catalyst

Check: Not applicable. Hirsh leads Percepta, an operating/transformation company, rather than a General Catalyst investment team. Founders seeking GC capital should contact an actual GC investor; enterprises seeking embedded AI transformation can contact Percepta.

Hirsh's operating thesis is that enterprise AI fails when organizations bolt point solutions onto legacy workflows or stop at pilots. Percepta embeds engineers, researchers and product managers inside critical institutions, combining frontier intelligence, proprietary data, domain trust and workforce adoption to redesign operations. The focus is production transformation in healthcare, government, manufacturing and finance—not venture selection or personal check writing.

Norrsken Impact Fund

Check: Norrsken VC publicly states €1M–€10M early-stage and growth tickets. It is a firm-level range, not evidence of Beata's personal signing authority.

Beata sources impact-driven technology across the Nordics and France, with declared interests in climate, energy and women's health. Her public 2026 outlook extends that lens to differentiated data for AI, technology-enabled healthcare pathways and space-based infrastructure where physical constraints enable new efficiency, sensing or manufacturing models.

Homerun Investments

Check: Homerun does not publish a George-specific check range or formal stage band. The firm invites technology companies with exceptional growth potential across its stated sectors. Founders should ask directly about vehicle, round and ownership fit rather than relying on Big Pi's separate historical parameters.

George brings an operator-investor lens shaped by building technology ventures, running Google Greece, leading advertising and media businesses, supporting Big Pi portfolio companies and founding an agricultural business. At Homerun, that experience maps to technology companies with exceptional growth potential across healthcare, industry, mobility and travel, real estate and agriculture. The core value is scaling teams, go-to-market and business development, not a narrow Web3 thesis.

Kleiner Perkins

Check: No personal or standard firm-wide check range is published. Ilya's official portfolio spans early and growth investments; Kleiner disclosed that its 2019 Series A investment in Rippling was $25M, but that one transaction is not a general range or personal limit.

Ilya invests in technology and novel business models capable of fundamentally reshaping industries. His portfolio connects AI-native professional work, enterprise operating systems, mathematical and software agents, physical AI, autonomous defense, logistics, healthspan, biotech, and financial infrastructure. A recurring pattern is a product-centric company that can redefine a large workflow and pair a technical discontinuity with a new go-to-market or business model.

First Round Capital

Check: First Round's published firm-wide initial checks are typically $1M–$7M, averaging about $3.5M; it has participated in rounds from $100K to $20M. No personal range is published for Hayley.

Hayley backs very early founders tackling real-world systems—especially healthcare, climate, supply chain, and commerce—that have been overlooked or written off as unsolvable. As a former founder, she evaluates both halves of the journey: the cold mechanics of execution and the emotional endurance of company-building, combining data-driven precision with direct, empathetic support.

Northzone (Web3)

Check: Not publicly disclosed. Northzone states that the firm invests from Seed through Growth and can remain a partner through pre-IPO; Wendy's current profile labels her personal focus as Early and says she likes to work with founders from as early as seed.

Wendy backs companies that change consumer behavior and expand the economic pie by capturing neglected externalities. She studies technology through people and behavior change, looking for a valuable position in a shifting value chain and a product capable of profound systemic change. Her hypothesis-led process separates factual and emotional evidence, makes assumptions explicit, challenges them through diligence, and still requires a differentiated leap of faith about fund-returning potential.

Craft Ventures

Check: No personal check-size range is published. Craft attributes investments from seed through growth to Jeff, but public round totals are company financings and not his personal allocation authority.

Jeff specializes in marketplaces, particularly vertical models that go deeper than horizontal incumbents. He evaluates density, liquidity, trust, network effects, take rate, gross profit, and capital-efficient growth, and has extended that operating lens into payments and AI applications. His recent Venture Partner transition preserves an early-stage, marketplace-oriented role while Craft's broader strategy shifts toward later stages and other categories.

Craft Ventures

Check: No personal check-size range is published. Public Craft examples involving Lainy include led seed, Series A, and Series C investments; company financing totals should not be interpreted as her personal check authority.

Lainy backs software and marketplaces that modernize complex vertical workflows. Her cases favor founder-market fit, a painful operational wedge, simple products built on technically difficult systems, and distribution that compounds through workflow adoption or network effects. Across logistics, work management, healthcare, labor, and creative tools, she looks for products that turn fragmented manual activity into an integrated platform and make a professional capability accessible to more users.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Reinhard Krickl invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Nora Kaarela invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Florian Eckhardt is listed in a Senior Advisor capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Lene Gerlach invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Lene Dragesund is listed in a Senior Office Manager capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Pål R. Jensen is listed in a Senior Advisor Operations capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Silje C. L. Ervik is listed in a Head of Legal capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Vilde Fredheim is listed in a Director, Investor Relations & Business Development capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Paal August Nordhagen is listed in a Director of Finance & Controlling capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Camilla Olsen is listed in a Impact & ESG Manager capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Markèta Chlubnovà invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Yun Yang invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Markus Dietrich invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Miao He invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Georgina Askeland invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Roger Franklin invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Walter Stockinger invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Ingrid Teigland Akay invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Zosia van Eesteren invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Wim Schimmel is listed in a Operational Partner capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Wessel van 't Klooster invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Varsha Ram Balapa is listed in a Climate Specialist - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Tristan Maguet invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Tom Klein Robbenhaar invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Susana Amorim invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stephanie Mooij is listed in a Head of Responsible Investment - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stephan Wachtveitl invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stefan Luzi invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stacey Vrijhof is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Sonia Hallen invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Silke Kranz invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Senay Sarsik is listed in a Office Manager Frankfurt - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Romy Wiering is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Robert Stein invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Rik Maerten is listed in a Junior Fund Controller - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Redmar Koene invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Raphael Arndt invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Rafael Natanek invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pommeline Korstanje invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pieter van der Meer invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pheline Mulitze invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Paulien Schippers is listed in a Finance Manager - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Oksana van Vliet is listed in a Legal & AML/KYC counsel - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Nellie Johnson is listed in a Executive Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Michel Verhoog invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Max Steeman invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Martin von Berg invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Marloes Herbrink is listed in a Finance Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Marion Pouillard invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Luna van den Brink is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Ludo Suykerbuyk is listed in a General Counsel & Compliance Officer - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Lara Hilgert invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Katharina Mono is listed in a ESG & Impact Analyst - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Kate Ebbenhorst is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Kasia Lorek invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Karthik Bolisetty invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Josephine Bogaerts invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Joep Muijrers invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Joep Heldens invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jelte Goettsch invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jasper van Gorp invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Janke Dittmer invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jan Willem Bakker is listed in a Head of Investor Relations / Partner - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Iskander Shadid invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Hugo de Bruin invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Henry Zubaida invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Forbion

Naarden, Netherlands

Tesi

Helsinki, Finland

Gilde Healthcare

Utrecht, Netherlands

Cambridge Innovation Capital

Cambridge, United Kingdom

Inveready

Barcelona, Spain

Primary Venture Partners

New York, New York

Radical Ventures

Toronto, Canada

Portugal Ventures

Porto and Lisbon, Portugal

Jungle Ventures

Singapore

Primo Capital

Milan and Rome, Italy

Crosslink Capital

Menlo Park, California

Investinor

Trondheim, Norway

Supernova Invest

Paris, France / Grenoble, France

Rubio Impact Ventures

Amsterdam, Netherlands

Drive Capital

Columbus, Ohio

Cultivation Capital

St. Louis, Missouri

Giant Ventures

London, United Kingdom and United States

b2venture

St. Gallen, Berlin, Munich and Luxembourg

ACV Capital

Jakarta, Indonesia and Singapore

Vertex Ventures Southeast Asia & India

Singapore

Base10 Partners

San Francisco, California

Chalmers Ventures

Gothenburg, Sweden

Parkwalk Advisors

London, United Kingdom

Ascension

London, United Kingdom

Engine Ventures

Cambridge, Massachusetts

M Ventures

Amsterdam, Netherlands

Amadeus Capital Partners

London and Cambridge, United Kingdom

Kurma Partners

Paris, France / Munich, Germany

Vertis

Naples and Milan, Italy

FoodLabs

Berlin, Germany

Defy Partners

Woodside, California

Collaborative Fund

New York, New York

IQ Capital

London and Cambridge, United Kingdom

Kaszek

Latin America

Newfund

Paris, France and Silicon Valley, United States

BioGeneration Ventures

Naarden, Netherlands

Forum Ventures

New York, San Francisco and Toronto

Novastar Ventures

Nairobi, Lagos and London

Hadean Ventures

Oslo, Norway and Stockholm, Sweden

Mercia Ventures

United Kingdom

Ananda Impact Ventures

Munich and London

Folklore Ventures

Sydney, Australia

Indaco Venture Partners

Milan, Italy

RC Capital

Cincinnati, Ohio / Raleigh, North Carolina

Revent

Berlin, Germany

Correlation Ventures

San Diego and Palo Alto, California

Inspired Capital

New York, New York

Mucker Capital

Los Angeles, California

Vi Partners

Switzerland

Ship2B Ventures

Barcelona, Spain

Designer Fund

San Francisco, California

Fifty Years

San Francisco, California

XYZ Venture Capital

San Francisco, California

1984 Ventures

San Francisco and New York

Conexo Ventures

Madrid, Spain

Define Ventures

Silicon Valley, California

Founders Future

Paris, France / San Francisco, United States

Maveron

Seattle, Washington and San Francisco, California

Brandenburg Kapital

Potsdam, Germany

Claris Ventures

Turin, Italy

Eleven Ventures

Sofia, Bulgaria

SemperVirens Venture Capital

United States

Vespucci Partners

Budapest, Hungary

.406 Ventures

Boston, Massachusetts

7wire Ventures

Chicago, Illinois

Algebra Ventures

Cairo, Egypt

Boomerang Ventures

Indianapolis, Indiana

Clarevia

Madison, Wisconsin

FUSE

Bellevue, Washington

Inovo VC

Warsaw, Poland

Mantis VC

Los Angeles, California

Northstar Ventures

Newcastle upon Tyne, United Kingdom

Otium Capital

Paris, France

Tall Order Ventures

Melbourne, Australia

Whitecap Venture Partners

Toronto, Canada

BBG Ventures

New York, New York

Core Innovation Capital

United States

Do Ventures

Ho Chi Minh City, Vietnam

Kickstart

Salt Lake City, Utah

Nina Capital

Barcelona, Spain

R1 Capital

Columbus, Ohio

TenOneTen Ventures

Los Angeles, California

Offline Ventures

Mill Valley, California

Outsiders Fund

United States

ATX Venture Partners

Austin, Texas

Eniac Ventures

New York, New York

Heal Capital

Berlin, Germany

Intudo Ventures

Jakarta, Indonesia

Lifeline Ventures

Helsinki, Finland

Soulmates Ventures

Prague, Czech Republic

Ulu Ventures

Palo Alto, California

2048 Ventures

New York, New York

Ada Ventures

London, United Kingdom

CincyTech

Cincinnati, Ohio

Fika Ventures

Los Angeles, California

Keyhorse Capital

Lexington, Kentucky